Nimotop solution for infusions 50 ml. 10 mg. №5 vial

Description

Nimotop composition and release form
Active ingredient: nimodipine.
Available in the form of a solution for injection (10 mg / 50 ml).

Indications
Nimotop is used for the prevention / treatment of ischemic neurological disorders provoked by spasm of cerebral vessels due to subarachnoid hemorrhage (for example, with rupture of an aneurysm).

Contraindications:

• with intolerance to the components;
• with severe liver failure;
• with cerebral edema;
• with an acute increase in intracranial pressure;
• simultaneous administration of the oral form of this drug.

Children
Not for use in pediatrics.

Application during pregnancy and lactation
During pregnancy, this drug is used in exceptional cases (the doctor determines the appropriateness of the appointment).
If necessary, use by women who are breastfeeding, stop feeding for the period of therapy.

Method of administration and dosage
Nimotope is used immediately after the detection of signs of acute ischemia (subarachnoid hemorrhage) and is used for 5-14 days. For adults, in the first two hours, the solution is administered intravenously by drop infusion – 1 mg (5 ml) per hour. After two hours, the dose is increased to 2 mg (10 ml) per hour (30 μg / kg / hour). When administered, it is necessary to monitor hemodynamics in order to avoid a sharp decrease in blood pressure.
For patients with a body weight not exceeding 70 kg, as well as with labile arterial pressure, administration of the drug is started with a dose of 0.5 mg (2.5 ml) per hour.

Overdose
In acute overdose, severe arterial hypotension (pressure drop), nausea, bradycardia or tachycardia, disruption of the digestive tract, signs of disruption of the central nervous system occur.

Side effects:

• Digestive disorders: diarrhea, nausea, dry mouth, change in appetite, paralytic intestinal obstruction.
• Neurological disorders: sleep disorders, dizziness, cephalalgia, psychomotor hyperactivity, hyperkinesis, aggressiveness, depression.
• Cardiovascular disorders: a drop in blood pressure (especially against the background of an initial increase in its level), hot flashes, hyperemia, a feeling of heat, bradycardia, increased sweating, bradycardia / tachycardia.
• Hematological disorders: thrombocytopenia.
• Immune disorders: allergic reactions.
• Changes in laboratory data: an increase in the activity of transaminases, Lf, gamma-glutamyl transferase, changes in renal function indicators (an increase in the concentration of urea, creatinine in plasma).
• Local reactions: phlebitis, thrombophlebitis.

Storage conditions and periods
It is necessary to store at temperatures below +30 degrees Celsius for no more than 4 years. The solution must not be frozen. Parents must ensure the safety of their children by protecting their access to medication.